Prenetics Global Ltd — Major Shareholding Notification 2024

Nov 14, 2024

SC 13G/A 1 p24-3021sc13ga.htm PRENETICS GLOBAL LTD

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Prenetics Global
Limited
(Name of Issuer)
Class A Ordinary
Shares, par value $0.0015 per share
(Title of Class of Securities)
G72245122
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)
(Page 1 of 6 Pages)

---

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Page; Sequence: 1; Options: NewSection; Value: 2

CUSIP No. G72245122 13G/A Page 2 of 6 Pages

Field: /Page

1	NAME OF REPORTING PERSON Genetel Bioventures Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong SAR
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER 613,786 Class A Ordinary Shares
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 613,786 Class A Ordinary Shares
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 613,786 Class A Ordinary Shares
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.8%
12	TYPE OF REPORTING PERSON OO

Field: Page; Sequence: 2; Value: 2

CUSIP No. G72245122 13G/A Page 3 of 6 Pages

Field: /Page

1	NAME OF REPORTING PERSON Michael Yang Mengsu
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION China
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER 613,786 Class A Ordinary Shares
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 613,786 Class A Ordinary Shares
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 613,786 Class A Ordinary Shares
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.8%
12	TYPE OF REPORTING PERSON IN

Field: Page; Sequence: 3; Value: 2

CUSIP No. G72245122 13G/A Page 4 of 6 Pages

Field: /Page

Item 1(a).
The name of the issuer is Prenetics Global Limited (the “ Company ”).

Item 1(b).
The Company’s principal executive offices are located at Unit 703-706, K11 Atelier King’s Road 728 King’s Road, Quarry Bay, Hong Kong.

Item 2(a).
This Statement is filed on behalf of Genetel Bioventures Limited (“ Genetel ”), a Hong Kong private limited company and Michael Yang Mengsu (“ Mr. Yang Mengsu ”), the controlling shareholder of Genetel (collectively, the “ Reporting Persons ”).

Item 2(b).
The principal business office of each of the Reporting Persons is 7B Yardley Commercial Building, 3 Connaught Road West, Sheung Wan, Hong Kong.

Item 2(c).
Genetel is a Hong Kong private limited company. Mr. Yang Mengsu is a citizen of China (Hong Kong SAR).

Item 2(d).
Class A ordinary shares, par value $0.0015 per share (the “ Shares ”).

Item 2(e).
G72245122

Item 3.
Not applicable.

Item 4.
The percentage used herein is calculated based upon 10,636,254 Shares outstanding as of April 24, 2024, as reported in the Company’s Annual Report of Foreign Private Issuers on Form 20-F for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on May 1, 2024.
The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person and is incorporated herein by reference.
The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.

Field: Page; Sequence: 4; Value: 2

CUSIP No. G72245122 13G/A Page 5 of 6 Pages

Field: /Page

Item 5.
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following: ¨

Item 6.
Not applicable.

Item 7.
Not applicable.

Item 8.
Not applicable.

Item 9.
Not applicable.

Item 10.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Field: Page; Sequence: 5; Value: 2

CUSIP No. G72245122 13G/A Page 6 of 6 Pages

Field: /Page

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: November 14, 2024

GENETEL BIOVENTURES LIMITED
By:	/s/ George William Hunter Cautherley
Name:	George William Hunter Cautherley
Title:	Director
By:	/s/ Michael Yang Mengsu
Name:	Michael Yang Mengsu